Connect with us

Technology

Barrington James Announces Strategic Acquisition of S3 Science Recruitment

Published

on

LONDON, July 3, 2024 /PRNewswire/ — Barrington James, a global leader in Life Science Recruitment, proudly announces the acquisition of S3 Science Recruitment, a firm renowned for its expertise in drug discovery, medical research, and the broader field of life sciences. Terms of the transaction were not disclosed.

This strategic acquisition marks a significant milestone for Barrington James, enhancing the company’s commitment to expanding its client-service capabilities and supporting the development of cutting-edge technology. This integration will provide clients with greater access to exceptional talent on both a permanent and temporary basis.

Dan Barrington, CEO of Barrington James, stated: “We are thrilled to acquire S3 and expand our Human Capital services in Life Sciences. This acquisition enhances our offerings across Board and Executive partnerships, Permanent Recruitment, Contract Recruitment, Staffing, OSP, and FSP. S3’s expertise in Clinical and Pre-Clinical specializations, both on a temporary and permanent basis, will perfectly complement Barrington James’ comprehensive Life Science services, from Clinical to Post-Marketing, A.I., and beyond. We are excited to collaborate with Alex Barrie, and his team, and we look forward to significantly growing S3 in the coming years.”

Alex Barrie, Director of Recruitment at S3, stated: “Clients of S3 Science Recruitment can expect a seamless transition, marked by the same dedication to excellence and personalized service they have come to rely on. Like Barrington James, we are deeply committed to delivering exceptional value and support to all our clients. By integrating the strengths of both companies, we are not only maintaining our high standards but also elevating them. The exciting integration of S3 Science into Barrington James enables us to offer an even broader and more comprehensive range of staffing solutions, ensuring that our clients benefit from a superior recruitment experience.”

About Barrington James:

Barrington James is a global, industry-leading recruitment business serving the Pharmaceutical, Biotechnology, and Medical Device sectors. With a global presence and a team of hundreds of specialists, we deliver world-class recruitment solutions to life science companies of all sizes. Leveraging a network of over 6 million industry professionals and advanced AI platforms, our expert consultants provide a personalized approach to global life science recruitment. For more information, please visit barringtonjames.com.

About S3 Science Recruitment:

S3 Science Recruitment connects talented individuals with leading organizations and institutions across the UK, Europe, and the United States. Our mission is to enable groundbreaking discoveries and life-saving treatments today. Specializing in drug discovery, medical research, and the broader Life Sciences field, we support the UK’s leadership in developing cures and treatments. Since 2002, S3 Science Recruitment has helped Life Sciences organizations find passionate individuals dedicated to medical advancement, particularly in animal research. We believe attracting talent to this vital industry is just the beginning of greater achievements. For more information, please visit s3science.com.

CONTACT:
Amy Tilbury
Head of Marketing
Atilbury@barringtonjames.com
+44 (0) 1293 776644

Photo – https://mma.prnewswire.com/media/2452929/Barringtonjames.jpg

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/barrington-james-announces-strategic-acquisition-of-s3-science-recruitment-302188155.html

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

MATSON ANNOUNCES ADDITION OF 3 MILLION SHARES TO EXISTING SHARE REPURCHASE PROGRAM AND QUARTERLY DIVIDEND OF $0.36 PER SHARE

Published

on

By

HONOLULU, April 23, 2026 /PRNewswire/ — The Board of Directors of Matson, Inc. (NYSE: MATX), a leading U.S. carrier in the Pacific, approved adding three million shares to its existing share repurchase program and extending the program to December 31, 2029.  As of April 23, 2026, the existing share repurchase program had approximately 0.7 million shares remaining.  The Board also declared a second quarter dividend of $0.36 per common share.  The dividend will be paid on June 4, 2026 to all shareholders of record as of the close of business on May 7, 2026.

“We are pleased to announce an additional three million shares to our existing share repurchase program,” said Matt Cox, Matson’s Chairman and Chief Executive Officer.  “Since we commenced our share repurchase program in August 2021, we have repurchased approximately 14.3 million shares, or approximately 33% of the then outstanding shares, for a total cost of $1.3 billion.  Going forward, we will continue to be both disciplined and opportunistic in our capital allocation, and we remain committed to returning excess cash to shareholders to create additional shareholder value over the long-term.” 

Shares will be repurchased in the open market from time to time at the Company’s discretion, based on ongoing assessments of the capital needs of the business, the market price of its common shares and general market conditions.  The Company may enter into Rule 10b5-1 plans to facilitate purchases under the program.  The repurchase program may be suspended or discontinued at any time.

About the Company

Founded in 1882, Matson (NYSE: MATX) is a leading provider of ocean transportation and logistics services.  Matson provides a vital lifeline of ocean freight transportation services to the domestic non-contiguous economies of Hawaii, Alaska, and Guam, and to other island economies in Micronesia.  Matson also operates premium, expedited services from China to Long Beach, California, which includes cargo from other Asia origins, provides services to Okinawa, Japan and various islands in the South Pacific, and operates an international export service from Alaska to Asia.  The Company’s fleet of owned and chartered vessels includes containerships, combination container and roll-on/roll-off ships and barges.  Matson Logistics, established in 1987, extends the geographic reach of Matson’s transportation network throughout North America and Asia.  Its integrated logistics services include rail intermodal, highway brokerage, warehousing, freight consolidation, supply chain management, and freight forwarding to Alaska.  Additional information about the Company is available at www.matson.com.

Forward Looking Statements

Statements in this news release that are not historical facts are “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, that involve a number of risks and uncertainties that could cause actual results to differ materially from those contemplated by the relevant forward-looking statement, including but not limited to, statements about capital allocation plans, the timing, manner and volume of repurchases of common shares pursuant to the repurchase program, and use of excess cash.  These forward-looking statements are not guarantees of future performance.  This release should be read in conjunction with our Annual Report on Form 10-K and our other filings with the SEC through the date of this release, which identify important factors that could affect the forward-looking statements in this release.  We do not undertake any obligation to update our forward-looking statements.

View original content to download multimedia:https://www.prnewswire.com/news-releases/matson-announces-addition-of-3-million-shares-to-existing-share-repurchase-program-and-quarterly-dividend-of-0-36-per-share-302752377.html

SOURCE Matson, Inc.

Continue Reading

Technology

Accord Specialty Pharmacy Named Finalist in MMIT’s 11th Annual Retail Specialty Pharmacy Patient Choice Awards

Published

on

By

ORLANDO, Fla., April 23, 2026 /PRNewswire/ — Accord Specialty Pharmacy, an independent specialty pharmacy serving patients across multiple states, has been named a finalist in the MMIT Patient Choice Awards, a recognition based on patient-reported satisfaction and experience.

Accord was selected as the only independent pharmacy among finalists in its category, alongside national pharmacy organizations such as Walgreens Specialty Pharmacy and Walmart Specialty Pharmacy. This distinction highlights the company’s commitment to delivering personalized, high-touch care for patients managing complex and chronic conditions.

The MMIT Patient Choice Awards recognize specialty pharmacies that demonstrate excellence in patient satisfaction, service quality, and overall care experience. Finalists are determined based on direct patient feedback, making the recognition a meaningful reflection of the trust patients place in their pharmacy providers.

“Being recognized alongside national organizations and as the only independent finalist validates our belief that personalized, patient-centered care drives better outcomes. We are building a model that combines clinical depth, national reach, and operational flexibility to better serve patients, providers, and partners.” said AJ Patel, Founder and Pharmacy Manager of Accord Specialty Pharmacy.

Accord Specialty Pharmacy supports patients across complex specialty categories, including oncology, rare disease, and infusion, through a clinically driven, high-touch care model designed to improve access, adherence, and outcomes. The company’s approach emphasizes personalized support, responsive care coordination, and strong clinical engagement to help patients navigate complex therapies more effectively. With a growing national footprint and multi-state licensure, Accord is positioned to support patients, providers, and partners across diverse markets.

For more information, visit MMIT Announces Finalists of the 11th Specialty Pharmacy Patient Choice Awards – MMITNetwork.

About Accord Specialty Pharmacy:

Accord Specialty Pharmacy is an ACHC-accredited, multi-state licensed independent specialty pharmacy located in Central Florida, dedicated to delivering high-quality, patient-centered care for individuals managing complex and chronic conditions. Through personalized support, clinical expertise, and a high-touch approach, Accord helps patients navigate every step of their treatment journey. Learn more at www.accordspecialty.com.

CONTACT: contact@accordspecialty.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/accord-specialty-pharmacy-named-finalist-in-mmits-11th-annual-retail-specialty-pharmacy-patient-choice-awards-302752327.html

SOURCE Accord Specialty

Continue Reading

Technology

HAIVISION ANNOUNCES VOTING RESULTS FROM 2026 ANNUAL MEETING OF SHAREHOLDERS

Published

on

By

MONTRÉAL, April 23, 2026 /CNW/ – Haivision Systems Inc. (“Haivision” or the “Company”) (TSX: HAI) is pleased to announce the voting results from its annual meeting of shareholders held today in a virtual format.

A total of approximately 45.97 % of the issued and outstanding common shares of Haivision were represented at the meeting.

Election of Directors

Each of the six nominated directors of Haivision was elected as director of the Company with the following results:

Director

Votes
For

% Votes
For

Votes
Against

% Votes
Against

Miroslav Wicha

11,110,245

99.26 %

82,583

0.74 %

Harvey Bienenstock

11,155,137

99.66 %

37,691

0.34 %

Robin M. Rush

11,121,855

99.37 %

70,973

0.63 %

Neil Hindle

10,794,005

96.44 %

398,823

3.56 %

Julie Tremblay

10,941,969

97.76 %

250,859

2.24 %

Lee K. Levy II

9,084,418

81.16 %

2,108,410

18.84 %

2.   Appointment of Auditors

Deloitte LLP were reappointed auditors of the Company for the ensuing year with 12,492,582 (98.84%) votes cast in favour and 146,406 (1.16%) votes withheld.

3.   Approval of the Unallocated Awards under the Company’s Equity Incentive Plan

The Company’s unallocated awards were approved with 8,710,347 (77.82%) votes cast in favour and 2,482,481 (22.18%) votes cast against.

4.   Reapproval of Company’s Shareholder Rights Plan

The Company’s shareholder rights plan was approved with 10,572,490 (94.46%) votes cast in favour and 620,338 (5.54%) votes cast against.

Final voting results on all matters voted on at the meeting will be filed under Haivision’s profile on SEDAR+ at www.sedarplus.ca.

About Haivision

Haivision is a leading global provider of mission-critical, real-time video streaming and visual collaboration solutions. Our connected cloud and intelligent edge technologies enable organizations globally to engage audiences, enhance collaboration, and support decision making. We provide high quality, low latency, secure, and reliable live video at a global scale. Haivision open sourced its award-winning SRT low latency video streaming protocol and founded the SRT Alliance to support its adoption. Awarded four Emmys® for Technology and Engineering from the National Academy of Television Arts and Sciences, Haivision continues to fuel the future of IP video transformation. Founded in 2004, Haivision is headquartered in Montreal and Chicago with offices, sales, and support located throughout the Americas, Europe, and Asia. Learn more at haivision.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/haivision-announces-voting-results-from-2026-annual-meeting-of-shareholders-302752318.html

SOURCE Haivision Systems Inc.

Continue Reading

Trending